Figure 7 | Scientific Reports

Figure 7

From: Immune inhibitory receptor-mediated immune response, metabolic adaptation, and clinical characterization in patients with COVID-19

Figure 7The alternative text for this image may have been generated using AI.

Association between IRscore and disease state and drug efficacy. (A) Lung/body (L/B) weight ratio in 6 mg/kg LPS (n = 14) and control (n = 6) groups. (B) Weight loss before and after LPS administration. (C) Pathological alterations in lung tissue of mice in the LPS and control groups. H&E photos were magnified by 200. (D) Differences in the IRscore between the control (green) and 6 mg/kg LPS (orange) groups. The Mann–Whitney U test was used to assess the difference. (E) Differences in the IRscore between acute infection and healthy and convalescence phase patients in the GSE198256 cohort. One-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test was used to assess the difference. (F) Differences in the IRscore between severe and moderate and healthy patients with COVID-19 in the GSE152418 cohort. One-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test was used to assess the difference. (G) Blood samples of patients with COVID-19 treated with anakinra compound were collected before and after 7 days of medication. The changes in the IRscore before and after drug treatment are shown in the line graph. Dark pink upper triangles represent the IRscore of patients with COVID-19 before anakinra treatment. Light pink lower triangles represent the IRscore of patients with COVID-19 after anakinra therapy. The IRscores of the same patient before and after treatment were connected in a straight line. Asterisks represent the statistical P value (*P < 0.05; **P < 0.01; ***P < 0.001; ns no significance).

Back to article page